A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
Phase 2
18–65
2 sites in CA, KS
What this study is about
This Phase 2 study is focused on people with obesity. The primary outcome being measured is Part A - Number of treatment emergent adverse events (TEAEs).
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Part A - Number of treatment emergent adverse events (TEAEs), Part B - Relative change in body weight, Part C- AUC; the area under the UBT251 plasma concentration time curve
Secondary: Part A - AUC; the area under the UBT251 plasma concentration-time curve, Part A - Change in body weight, Part A - Cmax; the maximum plasma concentration of UBT251, Part A - Relative change in body weight, Part B - Change in body weight, Part B - Change in waist circumference, Part B - Number of TEAEs, Part C - Cmax; the maximum plasma concentration of UBT251
Endocrinology